Riskpilot← Back to searchSign inGet full accessCHIRON PHARMASYNTH AS
ASActiveOrg 983903827Arkitekt Ebbells Veg 26, 7041 TrondheimManufacture of basic pharmaceutical products · NACE 2110Est. 20011 employeeswww.chiron.no
Revenue 2024
NOK 26,1M
+9% vs 2023
EBITDA margin
-2.8%
-115% vs 2023
Equity ratio
59.0%
Financial strength
Net profit 2024
NOK -258K
-106% vs 2023
| Revenue | NOK 26,1M | +9% |
| EBITDA | NOK -722K | -115% |
| Net profit | NOK -258K | -106% |
| Total assets | NOK 32M | -3% |
| Equity | NOK 18,9M | -1% |
| Employees | 1 | — |
Legal name
CHIRON PHARMASYNTH AS
Org number
983903827
Legal form
Aksjeselskap
NACE code
2110 · Manufacture of basic pharmaceutical products
Founded
17. november 2001
Share capital
NOK 1 775 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Drive utvikling, produksjon og salg av kjemiske produkter, formidling og salg av kompetanse og alt som dermed står i forbindelse, samt delta i annen økonomisk virksomhet av interesse.
Address
Arkitekt Ebbells Veg 26, 7041 Trondheim
Website
www.chiron.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 11 031 | 10 926 | 15 919 | 23 984 | 26 102 |
| Staff expenses | −3 557 | −4 233 | −8 269 | −10 993 | −15 237 |
| EBITDA | 4 691 | 3 850 | 1 647 | 4 963 | −722 |
| Depreciation & amort. | −16 | −14 | −0 | −0 | −0 |
| EBIT | 4 675 | 3 836 | 1 647 | 4 963 | −722 |
| Net financials | 270 | 9 | 246 | 104 | 465 |
| Profit before tax | 4 946 | 3 845 | 1 893 | 5 067 | −258 |
| Tax | 506 | 552 | 87 | 776 | −0 |
| Net profit | 4 440 | 3 292 | 1 806 | 4 291 | −258 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 21 661 | 25 541 | 28 458 | 32 931 | 31 964 |
| Equity | 14 439 | 15 772 | 17 578 | 19 118 | 18 860 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 7 222 | 9 769 | 10 880 | 13 813 | 13 104 |
| Total debt | 7 222 | 9 769 | 10 880 | 13 813 | 13 104 |
EBITDA margin
-2.8%
This company
15.8%
Market median
-118% vs market
20202024
Equity ratio
59.0%
This company
38.2%
Market median
+54% vs market
20202024
Return on equity
-1.4%
This company
18.4%
Market median
-108% vs market
20202024
Net profit margin
-1.0%
This company
8.1%
Market median
-112% vs market
20202024
Asset turnover
0.82×
This company
1.12×
Market median
+27% vs market
20202024
Debt / equity
0.69×
This company
0.62×
Market median
+11% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MS Chief Executive Officer | Chief Executive Officer | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2026 | |
| Chairman | 2023 | |
| Former (5) | ||
| Board of Directors | 2020 – 2023 | |
| Board of Directors | 2020 – 2023 | |
| Board of Directors | 2020 – 2023 | |
| Board of Directors | 2020 – 2023 | |
| Chairman | 2020 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Cpi Chiron Acquisition As
CHIRON PHARMASYNTH AS Board members of CHIRON PHARMASYNTH AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Marianne Sinnes | Chief Executive Officer | 0 companies |
| Huiling Liu | Board of Directors | 0 companies |
| Philip Rinaldi | Chairman | 0 companies |
| Cathinka Mæhlum | Board of Directors | 0 companies |
| Jon Borge Finset | Board of Directors | 0 companies |
| Jonathan Otto Salkin | Chairman | 0 companies |
| Jennifer Sarah Button | Board of Directors | 0 companies |
| Jon Eigill Johansen | Chairman | 0 companies |